GSK: invests E350m in Evreux site
(CercleFinance.com) - Bruno le Maire, French Minister of the Economy, Finance and Industrial and Digital Sovereignty, has welcomed GSK's decision to invest up to E350m (by end-2025) in its Evreux site to produce a new low-carbon formulation of Ventoline.
Half of GSK's emissions are generated by their metered-dose inhaler, Ventoline.
The new low-carbon formulation of Ventoline is currently undergoing clinical trials, with the potential to reduce the drug's carbon footprint by around 90%.
This investment includes the installation of three production lines dedicated to the production of Ventoline's new low-carbon formulation.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Half of GSK's emissions are generated by their metered-dose inhaler, Ventoline.
The new low-carbon formulation of Ventoline is currently undergoing clinical trials, with the potential to reduce the drug's carbon footprint by around 90%.
This investment includes the installation of three production lines dedicated to the production of Ventoline's new low-carbon formulation.
Copyright (c) 2023 CercleFinance.com. All rights reserved.